Tyra Biosciences is a clinical-stage biopharmaceutical company developing precision medicines that target the FGFR pathway. Its pipeline centers on oral FGFR inhibitors, including programs aimed at FGFR3-driven cancers and other solid tumors as well as selected skeletal conditions. The company serves an oncology and rare-disease niche where genetically defined patient populations are the focus of drug development.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -28.1 | — |
| Q2 2025 | 0 | — | -28.1 | — |
| Q3 2025 | 0 | — | -29.9 | — |
| Q4 2025 | 0 | — | -33.8 | — |
| Q1 2026 | 0 | — | -39.3 | — |
| Q2 2026 | 0 | — | -45.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: ArriVent BioPharma, Inc. (AVBP), Maze Therapeutics, Inc. (MAZE), Lakeland Financial Corporation (LKFN), InnovAge Holding Corp. (INNV), Schrödinger, Inc. (SDGR), Vistance Networks, Inc. (VISN)